ABEO · Abeona Therapeutics Inc.

The thesis

Abeona Therapeutics' ZEVASKYN skin-gene-therapy launch is growing, but the shares have kept sliding and the estimated 12 November 2026 third-quarter report is the first event that shows whether treated patients convert into recognized revenue. The adjusted close on 21 October 2026 was $4.51, which is 39.5% below the 52-week high of $7.46 and below the $4.96 close recorded on 8 October 2026.

The narrative is maturing: the story is well known after the 13 August 2026 second-quarter report, the 16 September 2026 eighth-center announcement and the 18 September 2026 FAYUVI approval release, and the shares have fallen 25.5% over three months. Searches of company news and filings found no Abeona announcement dated after 8 October 2026 that explains the decline. The 14-day relative strength index (RSI), a momentum gauge, was 36.1 on 21 October 2026, up from 31.3 on 8 October 2026 while the price fell further.

The New Technology Add-On Payment (NTAP) designation from the Centers for Medicare & Medicaid Services took effect on 1 October 2026. Abeona has not disclosed a revenue amount tied to it.

Bullish and bearish views on Abeona Therapeutics Inc.

The bull case on Abeona Therapeutics Inc. (ABEO), in brief: Product revenue is growing. The bear case: Revenue lagged treatments last quarter.

Bull case

• Product revenue is growing. Abeona reported $11.4 million of second-quarter 2026 ZEVASKYN revenue on 13 August 2026, up 31% from $8.7 million in the first quarter.
• Treatment activity continued into the third quarter. The same release said 12 patients had been treated since launch, five of them in the second quarter and three more in the third quarter to date. Seven qualified treatment centers were active at that point.
• Center network keeps widening. Abeona named University of Florida Health its eighth qualified treatment center on 16 September 2026 and said patient identification and onboarding had begun. The third-quarter treated-patient count is the first test of whether added centers raise throughput.
• Reimbursement support is now in effect. NTAP status became effective 1 October 2026 and can raise hospital payment for Medicare patients. The first full quarter with it in place is the fourth quarter of 2026.
• Partner approval adds an income line. Abeona confirmed on 18 September 2026 that Ultragenyx received U.S. approval for FAYUVI and that Abeona is eligible for milestones and royalties on future sales. The release gave no sales forecast.
• Analyst targets sit far above the price. Roth Capital initiated coverage with a $17 target and Cantor Fitzgerald raised its target from $28 to $30, per Benzinga's ratings record dated 18 September 2026. Both are third-party views that no quarterly report has yet tested.

Bear case

• Revenue lagged treatments last quarter. Abeona treated five patients in the second quarter but recognized revenue for four, because one manufacturing batch yielded fewer sheets than the threshold. Five observations are too few to establish a success rate. A repeat gap in the third-quarter report would show the problem persists.
• The price keeps falling without news. The close of $4.51 on 21 October 2026 compares with $4.96 on 8 October 2026 and $5.40 on 25 September 2026, the latter following the center and FAYUVI announcements. Good news in September did not hold the shares up.
• Losses are widening against falling cash. Abeona reported a net loss of $17.1 million for the first quarter and, per a Stock Taper summary, $20.2 million for the second.
• Financing risk follows a falling price. An equity raise would dilute holders at a lower price than the stock traded at in the summer. No offering has been announced in the filings reviewed.
• FAYUVI royalty value is undefined. The 18 September 2026 release did not quantify expected royalties, and Ultragenyx has not reported sales.

Price setup

The 21 October 2026 close of $4.51 sits 39.5% below the 52-week high of $7.46. The prior note's weekly-close line of $5.60 broke with the weekly close of $5.42 on 11 September 2026 and has not been recovered. The prior note's daily-close line of $4.50 has not fired: the 21 October 2026 close is one cent above it.

The RSI of 36.1 is above the 31.3 reading on 8 October 2026, which means the pace of decline has slowed even as the price made a lower close. No rising moving average sits near the price, so no gap-above-average crowding is visible. The one crowding fact is the approaching earnings date: the estimated report on 12 November 2026 is about three weeks away.

Catalysts, next 30 days

• ~12 November 2026 (est.): Third-quarter 2026 results and business update. Abeona has not confirmed the date; its third-quarter 2025 report came on 12 November 2025. The report shows treated patients against recognized revenue, the center count, cash and any commentary on NTAP.

No other dated company event falls inside 30 days. A financing announcement, if any, would be undated.

What would change the view

The case breaks if the third-quarter report again shows revenue recognized for fewer patients than were treated, or if the treated-patient count is flat or lower despite eight qualified centers. An equity offering, at-the-market sales program or new registration statement would also weaken it. On price, a daily close below $4.25 would extend the slide below the $4.50 line that the shares are now testing.

The case strengthens if the third-quarter report shows revenue recognized for every treated patient, a higher treated-patient count than the five in the second quarter, and cash that supports the launch without new equity.

What it trades with

Abeona trades with small-cap gene-therapy and rare-disease companies, which depend on risk appetite for unprofitable biotechs. Its share price in the last month moved without a company announcement, which points to sector or flow influences rather than ZEVASKYN news. FAYUVI links Abeona to Ultragenyx's commercial execution, but only through future royalties and milestones.